Amdipharm: From Pharmacist to Pharma Firm

Amdipharm was set up in April 2003 to find and market niche products in areas of real clinical need, considered too small-or unsexy-for larger players. Wholly-owned by UK-based distributor and wholesaler Waymade Healthcare, which started out as a chain of pharmacies, Amdipharm's management reckons that the group's experience across the drug distribution chain, particularly at the buyer's end, and its proven deal making prowess, will help it achieve its aim of becoming a successful European pharma company.

The latest trend in the Big Pharma industry, given the dearth of new blockbusters coming through R&D, may be to go specialist, but it's still all relative. Pfizer Inc. 's co-promotion of Merck Serono SA 's interferon-beta drug Rebif for multiple sclerosis still involves a $550 million drug; Roche sells cancer products worth several hundred million in annual sales. These products may never be blockbusters, but they're still large enough to leave plenty of far smaller drugs off the bottom of pharma's priority list. Consolidation—both between Big Pharma and with biotechs—will likely continue to throw up stray compounds, or drugs which must be sold to satisfy increasingly stringent competition laws.

All of which endorses the strategy of firms like Amdipharm Mercury Ltd. , a wholly owned subsidiary of UK...

More from Global Vision

More from In Vivo

AI In Biologics Discovery: The Expensive Bet On Unproven Promise

 
• By 

Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.

Kris Joshi Named Norstella CEO, Prioritizes AI Innovation

 
• By 

Joshi joins the parent company of Citeline, which houses flagship publications In Vivo, Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.

Deals Shaping The Industry, June 2025

 
• By 

An interactive look at pharma, medtech and diagnostics deals made during June 2025. Data courtesy of Biomedtracker.